




MEDICINAL PRODUCTS 2020

ARCA biopharma Inc.
Rank 30 of 52





RealRate

MEDICINAL PRODUCTS 2020

ARCA biopharma Inc.
Rank 30 of 52



The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 218% points. The greatest weakness of ARCA biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 21%, being 25% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	8,480
Assets, Non-Current	46
General and Administrative Expense	3,981
Goodwill	0
Liabilities, Current	926
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-160
Other Liabilities	0
Other Net Income	0
Other Revenues	172
Property, Plant and Equipment, Net	10
Research and Development	1,833

Output Variable	Value in 1000 USD
Liabilities	926
Assets	8,536
Expenses	5,654
Revenues	172
Stockholders Equity	7,610
Net Income	-5,482
Comprehensive Net Income	-5,482
Economic Capital Ratio	21%